A pioneering study presented at the 22nd ENETS Conference in Krakow, Poland has highlighted the clinical potential of AI-assisted pathology in neuroendocrine neoplasms (NEN). Led by PD Dr. med. Daniel Kaemmerer, the study evaluated Mindpeak’s AI-powered pathology algorithms for SSTR2A and Ki-67 immunohistochemistry (IHC) scoring, demonstrating impressive clinical-grade performance.

Key findings include:

• 92% agreement with manual evaluation for SSTR2A (positive vs. negative)
• High interobserver reliability for Ki-67 (Krippendorff’s α = 0.83)
• System usability score (SUS) of 75, indicating strong user satisfaction

Dr. Kaemmerer emphasized the impact of AI in pathology, stating:

“AI is not replacing pathologists—it’s empowering them! This study confirms that AI-powered digital pathology is no longer a vision for the future but a reality today. Mindpeak’s AI software enhances efficiency and accuracy, enabling faster and more reliable diagnoses.”

This proof-of-concept study marks a significant step toward integrating AI into routine pathology, enhancing diagnostic precision and reproducibility.